Percutaneous Electrical Nerve Field Stimulator System for Functional Abdominal Pain Disorders (IB-Stim)
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity and coverage criteria for the IB-Stim percutaneous electrical nerve field stimulator in pediatric patients with functional abdominal pain disorders (including IBS) and indicates prior authorization requirements for Medicare Advantage and Commercial plans.
No material clinical or coverage changes in this revision.
Medical Necessity and Coverage Criteria
Medicare Advantage and Commercial: Medical necessity criteria
Covered when ALL of the following are met
All conditions required for medical necessity
All uses of the percutaneous electrical nerve field stimulator system (IB-Stim) that do not meet the medical necessity criteria specified below are considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products.
Services that are determined to be not medically necessary or that are non-covered benefits are treated as exclusions under the member's benefit plan. Providers should verify member-specific benefits and eligibility with the provider call center or the member's subscriber agreement, which supersedes this medical policy.
Use of IB-Stim is considered not medically necessary when the patient does not meet the specified criteria: the patient is outside the 11–18 years age range; does not have a ROME IV–defined functional gastrointestinal disorder (including functional abdominal pain, functional abdominal pain syndrome, irritable bowel syndrome, functional dyspepsia, or abdominal migraine); organic GI disease has not been ruled out; GI symptoms have been present for less than 9 months; the patient has not tried and failed at least one medication in each required category (acid suppression, antispasmodics/motility agents, and neuromodulators) in addition to diet modification; or the patient has a contraindicated history such as a cardiac pacemaker, hemophilia, or psoriasis vulgaris.
If services are determined to be not medically necessary or are non-covered benefits, providers may not charge the member for those services unless the member was informed in advance and provided written agreement to pay at their own expense; refer to the participation agreement for applicable billing provisions.
Required Conservative Treatments Before Coverage
Diet modification plus medication trials in three classes
Conservative treatment required prior to consideration of IB-Stim
Medication failures must be in addition to attempted diet modification
Procedure and Billing Codes
| 64567 | Percutaneous electrical nerve field stimulation, cranial nerves, without implantation (New Code Effective 1/1/2026) |
| 0720T | Percutaneous electrical nerve field stimulation, cranial nerves, without implantation (Code Deleted Effective 12/31/2025) |
Prior Authorization, Documentation, and Billing Guidance
Prior authorization required for Medicare Advantage; recommended for Commercial
Prior authorization must be obtained for Medicare Advantage members; prior authorization is recommended for Commercial product members. CPT 64567 is the code noted as medically necessary when criteria are met (effective 1/1/2026).
- Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products.
- CPT 64567 is considered medically necessary when the coverage criteria are met (see Coding section).
Confirm benefits and eligibility prior to service
Verify member benefits and eligibility before providing IB-Stim; benefits vary by group/contract and the subscriber agreement or evidence of coverage governs coverage decisions.
- Refer to the Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable benefits.
- For member-specific determinations, contact the provider call center.
Medication failure requirement — trials in three classes
Document that the patient tried and failed at least one medication in each of three medication categories (acid suppression; antispasmodics/motility agents; and neuromodulators) in addition to diet modification before IB-Stim is considered medically necessary.
- Acid suppression: H2-blockers or PPIs.
- Antispasmodics/motility: hyoscyamine, dicyclomine, erythromycin/linaclotide, prucalopride.
- Neuromodulators: amitriptyline, nortriptyline, gabapentin, periactin, aprepitant.
Document complete medical necessity elements before submission
Ensure documentation supports all medical necessity elements in the policy (age 11–18, ROME IV diagnosis, organic disease ruled out, ≥9 months of symptoms, required medication failures, and absence of listed contraindications) before requesting authorization.
- Age: 11–18 years.
- Diagnosis: ROME IV defined functional gastrointestinal disorder.
- Duration: GI symptoms present ≥9 months.
- Contraindications: no history of cardiac pacemaker, hemophilia, or psoriasis vulgaris.
Check contract-specific prior auth and benefit variations
Benefits and prior authorization practices may vary by contract—refer to the member’s Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for contract-specific rules.
- Prior authorization is required for Medicare Advantage and recommended for Commercial products, but benefit coverage is determined by contract documents.
Contact provider call center for member-specific determinations
For member-specific benefit and eligibility questions, contact the provider call center; the subscriber agreement or employer agreement governs coverage and supersedes this policy.
- Call the provider call center for determinations tied to the member’s plan.
Coverage denial risk if medical criteria unmet
Use of IB-Stim that does not meet all listed medical criteria is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products and may be denied.
- All other uses that fail to meet the policy criteria are considered not covered/not medically necessary.
Do not bill members for services denied or non‑covered without written member agreement
If services are determined not medically necessary or are non-covered benefits, providers may not charge the member unless the member was informed and agreed in writing in advance to pay; check participation agreements for applicable provisions.
- Do not bill members for denied/non‑covered services unless there is a prior written agreement from the member consenting to self-pay.
Device and Term Definitions
Treatment Frequency and Limits
Imaging and Placement Guidance
No imaging required for electrode placement
No additional imaging is required for electrode placement; a pen light is used with the device to visualize neurovasculature for proper placement.
Background and Device Description
IB-Stim is a disposable, non-implantable percutaneous electrical nerve field stimulation device applied to the external ear. The device is battery-operated with a multi-lead electrode array placed on auricular locations to stimulate branches of cranial nerves (including V, VII, IX, and X) and is intended to modulate central pain pathways for up to the duration of a treatment period described in the literature (commonly worn for periods such as 5 days/120 hours in study regimens).
Not Covered / Exclusions
IB-Stim is not covered when used outside the specified pediatric age range (11–18 years), when the patient does not have a ROME IV functional gastrointestinal diagnosis, when organic GI disease has not been excluded, when GI symptoms have been present for less than 9 months, or when the required trial and failure of at least one medication in each of the three categories (acid suppression, antispasmodics/motility agents, and neuromodulators) plus diet modification have not been documented. The device is also not covered for patients with contraindicated conditions listed in the criteria (history of cardiac pacemaker, hemophilia, or psoriasis vulgaris). Additionally, services judged to be not medically necessary or non-covered under the member's benefit plan remain exclusions and may not be billed to the member except as allowed by the policy when the member provided prior written agreement to pay.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.